SECOND ANNUAL
Fluorescence-Guided Surgery
Brain Tumor Symposium

DECEMBER 6, 2019
Icahn School of Medicine at Mount Sinai
Leon and Norma Hess Center for Science and Medicine
Bonnie M. Davis, MD and Kenneth L. Davis, MD Auditorium
1470 Madison Avenue
New York, NY

Course Director
Constantinos G. Hadjipanayis, MD, PhD
Site Chair, Department of Neurosurgery, Mount Sinai Union Square
Professor of Neurosurgery & Oncological Sciences
Director, Neurosurgical Oncology
Director, Brain Tumor Nanotechnology Laboratory
Mount Sinai Health System

mssm.cloud-cme.com/FGS
Registered neurosurgeons will hear experts from both the U.S. and Europe discuss fluorescence-guided surgery. The goal is to equip our healthcare providers with the tools they need to provide optimum health care to their patients.

**PROGRAM OBJECTIVES**
Define the use of fluorescence-guided surgery (FGS) for gliomas to practicing neurosurgeons, discuss the use of FGS for different tumor types, and discuss the use of FGS in combination with other intraoperative visualization technologies.

**WHO SHOULD ATTEND?**
Neurosurgeons, Allied Health Professionals, Residents, and Fellows.

**ACCREDITATION**
The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**CREDIT DESIGNATION**
The Icahn School of Medicine at Mount Sinai designates this live activity for the maximum of 8.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**VERIFICATION OF ATTENDANCE**
Will be provided to all professionals.

**COURSE LOCATION**
The Bonnie M. Davis, MD and Kenneth L. Davis, MD Auditorium, 2nd Floor, 1470 Madison Avenue (between 101st and 102nd streets), New York, NY. Directions and parking: www.icahn.mssm.edu/about/visiting.

**ACCOMODATIONS**
Discounted sleeping rooms can be reserved with our Housing Manager, Denise Newman. Cell/text: 347-236-7181; phone: 718-835-4911; email: dnew229@aol.com.

**SPECIAL NEEDS**
The Icahn School of Medicine at Mount Sinai is in full compliance with provisions of the Americans with Disabilities Act (ADA) and is accessible for individuals with special needs. If you require special accommodations, call the Office of CME at 212-731-7950.
7:00 am  Registration and Breakfast

7:30  Welcome and Symposium Overview  
Constantinos G. Hadjipanayis, MD, PhD

7:45  Introduction to Fluorescence-Guided Surgery (FGS)  
Constantinos G. Hadjipanayis, MD, PhD

8:15  Current and Future State of Fluorescence-Guided Surgery for Brain Tumors  
Walter Stummer, MD, PhD

9:00  5-ALA Fluorescence-Guided Surgery for High-Grade Gliomas  
Shawn Hervey-Jumper, MD

9:30  5-ALA Fluorescence-Guided Surgery for Low-Grade Gliomas  
Nader Sanai, MD

10:00  BREAK WITH EXHIBITORS

10:30  Microscope and Handheld Fluorescence-Guided Surgery of Brain Tumors  
David Roberts, MD

11:00  5-ALA for other CNS Tumors and Stereotactic Biopsies  
Georg Widhalm, MD, PhD

11:30  Use of Fluorescence-Guided Surgery and Intraoperative MRI (iMRI)  
Ian Y. Lee, MD

12:00 pm  LUNCH & Fluorescence-Guided Surgery Simulation 1 (Seminar Room B)  
Walter Stummer, MD, PhD and Constantinos G. Hadjipanayis, MD, PhD

1:00  Second Window Indocyanine Green for Identification of Brain Tumors  
John Lee, MD

1:30  Use of Fluorescein for Brain Tumor Fluorescence-Guided Surgery  
Jeffrey Bruce, MD

2:00  Tozuleristide Fluorescence-Guided Surgery of Pediatric Brain Tumors  
Amy Lee, MD

2:30  Antibody-Labeled Fluorophores (Cetuximab-IRDye800) for GBM Resection  
Gerald Grant, MD

3:00  BREAK WITH EXHIBITORS & Fluorescence-Guided Surgery Simulation 2 (Seminar Room A)  
Walter Stummer, MD, PhD and Constantinos G. Hadjipanayis, MD, PhD

4:00  5-ALA Photodynamic Therapy for GBM  
Nicolas Reyns, MD, PhD

4:30  Panel Discussion: How Do I Use Fluorescence-Guided Surgery in my Practice?  
All Faculty

5:00  Completion of Symposium
Faculty

Course Director
Constantinos G. Hadjipanayis, MD, PhD
Site Chair, Department of Neurosurgery, Mount Sinai Union Square
Professor of Neurosurgery & Oncological Sciences
Director, Neurosurgical Oncology
Director, Brain Tumor Nanotechnology Laboratory
Mount Sinai Health System

Guest Faculty
Jeffrey Bruce, MD
Vice-Chairman of Academic Affairs
Department of Neurosurgery
Co-Director, Brain Tumor Center
Columbia University Irving Medical Center

Gerald Grant, MD
Professor of Neurosurgery
Division Chief of Pediatric Neurosurgery
Stanford University Medical Center

Shawn Hervey-Jumper, MD
Associate Professor of Neurological Surgery
University of California, San Francisco

Amy Lee, MD
Associate Professor of Neurological Surgery
Seattle Children’s Hospital
University of Washington School of Medicine

Ian Y. Lee, MD
Co-Director, Hermelin Brain Tumor Center
Director, Spinal Neuro-Oncology
Department of Neurosurgery
Henry Ford Hospital

John Y.K. Lee, MD
Associate Professor
Departments of Neurosurgery and Otolaryngology
University of Pennsylvania

Nicolas Reyns, MD, PhD
Professor of Neurosurgery
University of Lille Sciences and Technology
Lille, France

David Roberts, MD
Professor of Neurosurgery and Neurology
Geisel School of Medicine
Dartmouth-Hitchcock Medical Center

Nader Sanai, MD
Najafi Professor of Neurological Surgery
Director, Division of Neurosurgical Oncology
Director, Ivy Brain Tumor Center
Barrow Neurological Institute

Walter Stummer, MD, PhD
Professor and Chairman
Department of Neurosurgery
University of Munster
Munster, Germany

Georg Widhalm, MD, PhD
Assistant Professor
Department of Neurosurgery
Medical University of Vienna
Vienna, Austria

FACULTY DISCLOSURE
It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.